Beyond Opioids: Can Medicine Finally Fix Chronic Pain?

The Question

Every year, more than 80,000 Americans die from opioid overdoses. That's more than die in car crashes. Meanwhile, 50 million people live with chronic pain — pain that has lasted for months or years — and medicine's answer has largely been the same pill it's been reaching for since the 1990s. Something is clearly broken.

Our prediction is specific: by 2032, non-opioid treatments will become the default first choice for chronic pain in most wealthy healthcare systems. We put the probability at 72%. The starting gun fired in January 2025, when the FDA approved the first genuinely new kind of pain drug in over two decades. But new drugs take time to spread — historically 8 to 12 years from approval to widespread use. The revolution is real. Whether it reaches patients fast enough is what this analysis is built to answer.

What the Evidence Shows

In January 2025, the FDA approved a drug called suzetrigine — brand name Journavx. What makes it different from every painkiller that came before? It targets a single type of channel in pain-sensing nerve cells, called Nav1.8, without touching the brain's broader reward system. Opioids work by flooding the brain with signals that dull pain but also trigger euphoria, dependence, and, in too-high doses, stopped breathing. Suzetrigine sidesteps all of that. Early trials showed it matched opioids for post-surgical pain with none of the addiction risk.

That's not the only frontier. Spinal cord stimulation — a small device implanted near the spine that sends gentle electrical pulses to interrupt pain signals — is delivering 50 to 80% pain relief in patients who've tried everything else. Wearable versions are bringing the same idea to the market without surgery. And AI-assisted pain mapping, using brain scans and machine learning to identify individual "pain fingerprints," is moving from labs toward clinics. Doctors might soon be able to see your pain rather than ask you to score it from one to ten.

Then there's the psychedelic frontier. Ketamine — already FDA-approved for depression — is being used off-label for conditions like complex regional pain syndrome, a nerve disorder so severe patients have described it as feeling like their limb is on fire constantly. Psilocybin (the active ingredient in magic mushrooms) is in trials at Johns Hopkins for cluster headaches and phantom limb pain, two conditions with almost no good treatments. Neither is a mass-market solution yet. But they represent a fundamental shift in how scientists think about pain — less as a signal from the body, and more as something the brain is actively constructing.

Why This Is Happening

The financial case for change is overwhelming. Chronic pain costs the US between $560 billion and $635 billion a year — in treatment, missed work, and lost productivity. That dwarfs the cost of developing any new drug or device. Employers and insurers have powerful financial reasons to want better options, and that pressure is now flowing into research budgets.

The opioid backlash has created a treatment vacuum. Stricter prescribing rules — introduced after the overdose crisis — have pushed many doctors to cut back on opioids dramatically. That's saved lives. It's also left millions of chronic pain patients without adequate treatment, tapering off drugs they depended on with no alternative offered. New non-addictive options would give doctors the confidence to treat pain aggressively again — without fear of creating the next crisis.

Pain science itself has been transformed. We now know that chronic pain isn't just an injury that won't heal. It involves real changes in how the brain is wired — the nervous system essentially learns to keep the alarm ringing even after the original cause is gone. Trauma, stress, and adverse childhood experiences can all amplify pain signals in measurable ways. That opens up entirely new approaches: not just numbing the signal, but reprogramming the system sending it.

What Could Happen

What Can We Do

You don't have to wait for new drugs. The evidence for non-opioid approaches is already strong — it's just underused. Regular low-impact exercise, like walking or swimming, reduces chronic pain intensity by around 30% on average. It works partly through the body's own painkilling chemicals, and partly by reversing some of the nervous-system changes that keep pain alive. Sleep matters too. Poor sleep makes pain worse — it literally lowers your pain threshold — and a type of therapy called CBT-I (cognitive behavioural therapy for insomnia) can break that cycle without medication.

If your pain has roots in trauma or stress — and research increasingly suggests it often does — standard physical treatments may not be enough on their own. Pain psychologists, still rare in most healthcare systems, can help address the psychological dimension that physical medicine alone misses. Asking your doctor about a referral is worth trying, even if access is limited.

At the policy level, the gap is stark. The NIH spends about $600 million a year on pain research. It spends over $6 billion on cancer. Closing that gap would accelerate the therapies that are already in development and build the evidence base to ensure they reach everyone equally — not just those who can afford to pay out of pocket for a $500-a-month drug.